RESEARCH PAPER

Bridging Safety and Compliance: The Dual Role of Ion-Exchange Resins in Pediatrics and Abuse-Deterrent Drug Delivery

Santosh Kesarpu [1*], Rajanikant Patel[2]

[1]*Associate Director - R & D Product Development, Granules Pharmaceuticals Inc., 3701 Concorde Pkwy, Chantilly, Virginia 20151, USA, ORCID:0009-0007-9557-3459*
[2]*Senior Scientist - R & D Product Development, Granules Pharmaceuticals Inc., 3701 Concorde Pkwy, Chantilly, Virginia 20151, USA ORCID:0009-0005-4989-2913*

Received: 24th Sep, 2025; Revised: 28th Oct 2025; Accepted: 18th Nov, 2025; Available Online: 1st December, 2025

ABSTRACT
Ion-exchange resin (IERs) are also reported to ensure enhanced safety of drugs, especially pediatric preparations and abuse-deterrent systems (ADS). These resins are being modeled to bind drug molecules, whereby the release can be controlled, the taste can be masked, and the adherence to the patients can be improved. Pediatricians have discovered that in the area where drug adherence is critical, IERs assist in mitigating dosage issues and drug palatability, a factor that has at least served to support medication compliance by at least 25%. In the meantime, IERs will serve as a discouragement to the abuse of drugs, as it will make it more difficult to abuse the drug. The dual advantage in achieving therapeutic effect and safety prioritizes the applicability of the IERs specifically in chronic pediatric care, including ADHD and asthma care, and addressing the rising issue of the abuse of opioids and stimulants. This study synthesizes the results of clinical interventions and regulatory publications (2019-2024) to assess the usefulness of IER-based regimes in enhancing pediatric adherence and preventing abuse. Findings indicate that compliance with safety has greatly improved, such as a 30% decrease in malignancy and a 25% decrease in compliance. These results demonstrate a promising role of IERs to enhance safety and compliance in drug delivery systems, with broad validity in the pharmaceutical design and in the health policy of the population.

Keywords: Ion-exchange resins (IERs), Pediatric formulations, Abuse-deterrent systems (ADS), Drug delivery safety, Patient adherence
How to cite this article: Kesarpu S, Patel R., Bridging Safety and Compliance: The Dual Role of Ion-Exchange Resins in Pediatrics and Abuse-Deterrent Drug Delivery. Int J Drug Deliv Technol. 2026;16(1): 148-159, DOI: 10.25258/ijddt.16.1.16
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Ion-exchange resins (IERs) are insoluble polymers that are crosslinked and have fixed anionic or cationic groups that reversibly bind ionizable drugs to create drug-resin complexes (resinates). IERs have been used since being introduced to pharmaceutics in the 1950s to allow the masking of flavors, stabilization, and controlled release in both liquid and solid states. Dextromethorphan Polistirex Suspensions have been marketed to give 12-hour antitussive action, and hydrocodone-chlorpheniramine Polistirex suspensions, in which an ion-exchange polymer matrix and a permeable coating mediate release. The products that show how resinates allow error of sustained release in liquids are one of the niches that cannot easily be realized with conventional matrices. Industrial environment favorable: the global ion-exchange resin market is estimated to be valued at approximately USD 1.921 billion in 2024, and the general growth rates are calculated at 4.860% annual growth rates. Discounting water treatment, which leads the volume, is the rapid growth of pharmaceutical and specialty grades, as independent reports are showing a compounded growth rate of 5.8% CAGR by 2030. Such scale and growth are an indication of a robust supply base and remaining room for innovation where pharmaceutical adaptation is concerned.

Oral drugs need to provide therapeutic exposure and guard against avoidable damage. In pediatrics, the risk is in the home: in the United States alone, approximately 63,000 out-of-hospital medication errors each year occur in children under the age of six -one event per four out of five-liquid medicines are the cause of one event every 8 minutes. In care environments, the literature on the background of ERP or inpatient reveals that the error rates attributed to prescription or dosing differ in the range of 10%-34% and they are commonly associated with weight-based calculations, inconsistent measurement tools, and workflow interruptions. Simultaneously, inappropriate use of solid oral dosage forms by crushing, extracting solvents, or subjecting them to heating conditions compromises the intended pharmacokinetics and leads to a threat to public health. The regulators hence promote the abuse-deterring design and standardized in-vitro manipulation testing in order to describe resistance to typical modes of tampering. The need to balance the performance of a specific

**Author for Correspondence: kesarpu.santosh@gmail.com*

therapeutic given along with these safety imperatives is a practical challenge to development teams as well as health systems.

IERs offer one practical and convenient platform to address the two groups of risk. Resin complexation in pediatric preparations prevents bitterness, allows metering using oral syringes, and facilitates a single or twice-daily liquid dosing by ion-exchange-controlled release, which makes the syrup more acceptably flavored and easier to use than unmodified syrups. At the same time, the ionic binding, bead size, and coating methods utilizing drug-resinate systems provide chemical and mechanical obstacles that delay the solvent extraction, restrict the syringeability following manipulation, and deflect the heat-facilitated release. Newer research and patent reports indicate that complexes based on IER can hit category-1 manipulation targets and retain bioavailability at intended usage, indicating that a potential viable way to integrate patient-controlled dosing with abuse-deterrent technologies within a single platform exists. The study aims to evaluate the effects of pediatric ready-to-mix formulations based on IER, in terms of safe use and adherence, weighted by a prescription pickup rate, palatability rate, correct-device rate, day-to-day rate of dose fidelity, and avoidable emergency revisits. It also evaluates the usefulness of IER complexation as an abuse-deterrent enabler by comparing the in-vitro manipulation results, the extraction yield, particle-size reduction effort, syringeability, and failure rates during heating/ alcohol stress to non-IER comparators to the enabler. The analysis focuses on measurable, operational measures that can be implemented by formulators, clinicians, and policy makers. This study is structured in various chapters. The literature review chapter also summarizes ion-exchange chemistry, marketed exemplar, pediatric safety epidemiology, and regulatory foundation to assess abuse-deterrent evaluation and labeling. The methods and techniques section is a description of the data sources, inclusion criteria, and analytic strategies of pooled adherence and manipulation-resistance, and also presents a description of a laboratory program that is different in resin type, drug-resin ratio, and coating architecture. In the experiments and results chapter, characterization, release kinetics, adherence, and palatability data, and manipulation-resistance data are presented. The discussion chapter contains the interpretation of effect sizes, generalizability, and implementation trade-offs, and in the concluding sections, the identification of future research directions and recommendations about the development of a pediatric and abuse-deterrent drug.

2. LITERATURE REVIEW

2.1 Historical Overview and Chemical Mechanism of IERs

Ion-exchange resins (IERs) are water-insoluble, cross-linked polymers with fixed ionic groups that reversibly interact with oppositely charged drug species to form a drug-resinate complex. Ever since the 1950s, pharmaceutics has used strong and weak cation exchangers (such as sulfonated styrene–divinylbenzene versus carboxylic methacrylates) and strong anion exchangers (quaternary ammonium matrices) to allow taste masking, stabilization, and controlled release of liquids and solids. Mechanically, drug liberation is through competitive interaction with physiological counter-ions (Na^+, K^+, Cl^-) and diffusion via the resin bead and any functional coatings. The ion-exchange capacity (meq/g), cross-link density, particle size distribution, coat thickness, and ionic strength and pH of the external medium are the factors that control release kinetics. In pediatric liquids, resin binding and bead architecture enable such release behavior of resin to be particularly advantageous, whereas in abuse-deterrent solids, resistance to solvent solicitation, thermal disturbance, and fast dispersion are provided [1]. Equilibrium binding isotherms, swelling ratios, in vitro dissolution at differing ionic strengths, and mechanical evaluation of bead integrity are normally combined in quantitative characterization to sensibly select resin type, drug: resin ratio, and bead coating scheme to match the desired clinical profile.

2.2 IERs in Pediatric Formulations

Pediatric medicine is effective when it is agreeable about taste, method of administration, and even the simplicity of the regimen, if it fits the routine of caregivers and school schedules. IERs play a part in three quantifiable fronts. Taste masking occurs due to ionic sequestration, reducing free-drug activity in some taste receptors; understanding of how palatability is evaluated by development programs on nine-point hedonic scales and electronic-tongue fingerprint with pragmatic objectives of improving the difference between medium scores of one to two points of free-drug activity versus non-resinated controls.

Figure 1 below shows the diagram that provides important issues that bring about the development of an effective pediatric formulation. This involves dose accuracy, ease of administration, and excipient and drug safety, which are all critical points in pediatric adherence. The values of taste, flavor, and smell are also pointed out, and these directly determine palatability, which is an essential aspect that helps children accept medication [2]. The IERs play a big role and help to cover the unpleasant taste and to make the drug sweeter and thus enhance compliance, which is gauged by palatability scores and development of practicality goals.



Figure 1: Key Factors for Creating Efficient Pediatric Formulations to Enhance Adherence.

Multi-dose liquids should also be metered and have uniform bottle life, resinates are compatible in thixotropic vehicles and have targets of relative standard deviation of ≤10% content-uniformity on in-use testing and label claim values of 90-110% of actual content percentage after opening in 28 days. Ion-exchange-controlled release allows once- or twice-daily schedule manipulation, which minimizes daily handling operations and daily allocation of cognitive resources after determining weight-related dosages. Reminder workflows must be devoid of notification fatigue, must schedule caregiver prompts in order of urgency, must override document directives, operational styles that suit patient-centered quiet-hours communication systems in clinical informatics, which strike a balance between timeliness of action and human factors.

2.3 IERs in Abuse-Deterrent Formulations (ADFs)

Complexation of resin in abuse-prone groups provides additional chemical and physical barriers to manipulation. Ionic binding increases how hard it is to violate the active drug with household solvents, bead microstructure makes it hard to reduce to insufflatable fines, and polymer overcoats hinder syringeability in heating or alcohol challenge. ADF laboratories have developed an objective endpoint to measure benefit: extraction performance compared to control (engineering target reduction 50% or higher across water, ethanol and isopropanol), portion doses recovered after grinding and challenging solvent, syngentable and filterability after thermal or solvent stress and in-vitro release after being manipulated (ex: less than 30% dose 15 minutes under tamper conditions).

IERs also have the ability to limit rapid draw-through even further when used with viscosity-inducing excipients in the vehicle. Even though real-world diversion is also multifactorial, such laboratory measures offer regulator-accepted surrogates of manipulation resistance. Notably, the bead-coating architecture designs to remove pediatric system release can be reused to understand solvent-and heat-resistant salting layers, and a single platform can be utilized to meet both adherence and tamper-resistance design requirements in an integrated manufacturing strategy.

2.4 Regulatory and Safety Framework

Special communication and reliable plumbing of data is needed to provide a believable safety case on IER-based pediatric and ADF products. Notification governance based on patient centricity, through quiet-hour windows, urgency tiering, and auditable overrides are directly of interest to adherence programs around sustained-release liquids and allows minimization of alarm fatigue without compromising responsiveness to clinically urgent exceptions; new informatics projects describe these operational controls and their implementation processes, whereby the transferable blueprint can be applied to coordinate care providers, pharmacists, and clinicians. Similarly, explainable-AI principles must also apply to risk dashboards, which indicate dosing-error trends or likely manipulation incidents; models revealing palatability-associated discontinuation risks, or abnormal refill results, must reveal another transparent rationale and artifact that a clinician can question to make decisions and fulfill oversight [3].

Due to the heterogeneity of evidence streams, manufacturing lots and resin batches, pharmacy fills, caregiver messages, and adverse-event accounts, master data management (MDM) is necessary to put together identifiers, implement data-quality regulations, trace lineage, and have a single source of truth in both pharmacovigilance and product-quality systems. An MDM layer enhances regulatory preparedness, legality, and business efficiency through automating the classification, governance, and integration of large volumes of records in both healthcare and supply-chain settings, allowing timely at-will benefit-risk evaluation of IER platforms.

2.5 Gaps in the Current Literature

Three implementation gaps are limiting. Some studies provide head-to-head comparisons of converting pediatric adherence measures to manipulation endpoints of the same IER system; optimization thus differentiates these silos instead of doing a multi-objective design that balances palatability, dose uniformity, pharmacokinetics, and tamper resistance simultaneously. Real-world evidence remains fragmented as the unstructured records in pharmacovigilance, poison-control calls, and emergency-department case reports are rarely sequentially reasoned in a form that might reveal non-noticable trends of dosing error or intention to tamper.

Dynamic-memory neural methods, which were initially designed to learn using natural-language inferences, show that iterative attention and episodic memory hops may dominate even more sophisticated text classification tasks than an embarrassingly simple baseline- an encouraging result that relates to such architectures adding value to learning post-market safety to IER products. Standardized pediatric palatability and in-use uniformity endpoint reports are inconsistently reported, which projects meta-analysis problems and external validity; harmonized protocols, shared data models, and transparent analytics would be required to extrapolate laboratory success to benefit population safety.

3. METHODS AND TECHNIQUES

3.1 Data Collection Methods

The data utilized in this research were obtained on the basis of three main sources: PubMed, ClinicalTrials.gov, and the WHO pharmacovigilance database. The search in PubMed brought 85 suitable studies, the majority of which were clinical trials and reviews published in the past five years (2019-2024). These articles concentrated on pharmacokinetics, safety, and efficacy of ion-exchange resins (IERs) in pediatric preparations as well as abuse-deterrent drug delivery systems. Besides PubMed, 20 trials that are focused on IER formulations in children or opioid misuse prevention were searched on ClinicalTrials.gov, and once again under the specified time frame [4]. The WHO

pharmacovigilance database offered 15 more reports that concentrated on adverse drug reactions with medications based on IER, with reports on post-marketing surveillance and post-incident reports worldwide.

Study inclusion criteria were stringent, as only peer-reviewed articles that included human subjects were to be included and published within the period of 2019-2024 in English. Studies that covered not only the formulations of abuse deterrent drugs but also abuse deterrent drugs in children were given priority. Besides the published works, 50 pediatric clinicians and 40 pharmacists took part in the survey to collect the expert opinion on the clinical usefulness and obstacles of working with IERs in practice. These surveys were aimed at addressing the most important problems, like patient adherence, palatability, safety concerns, and clinical outcomes. The responses were also statistically summarized as part of the analysis to give a real-life context to the results obtained in the literature [5].

3.2 Data Analysis

The literature collected underwent a quantitative and qualitative analysis of data. In the quantitative analysis, it was done by the application of meta-analysis, which implied the application of fixed-effect models to assess the joint effect sizes of connotations of the IER formula on pediatric adherence and abuse-deterrent performance. A p-value of less than 0.05 was used as the statistical significance level [6]. Meta-regression was also conducted in order to determine whether there were any moderator effects, such as resin type, drug-to-resin ratio, and stability of pH, on the recorded results. The effect sizes were also computed on the primary outcomes, including the rate of adherence improvement and reduction in the potential for abuse, emphasizing primarily those studies that have quantifiable outcomes.

Table 1: Summary of Data Analysis Methods and Key Outcomes

Analysis Type	Methodology	Focus	Key Outcomes
Quantitative Analysis	Meta-analysis with fixed-effect models to evaluate IER effects on pediatric adherence and abuse deterrence	Pediatric adherence and abuse-deterrent performance	Improvement in pediatric adherence, reduction in misuse potential
Meta-Regression	Meta-regression to identify moderator effects (e.g., resin type, drug-to-resin ratio, pH stability)	Moderator effects on IER performance	Identification of key factors affecting IER performance
Effect Sizes	Calculation of effect sizes for adherence improvement and reduction in abuse potential	Adherence improvement and abuse reduction outcomes	Quantifiable outcomes: adherence improvement, reduction in abuse potential
Qualitative Analysis	Thematic analysis to identify common themes in survey responses and qualitative research	Patient satisfaction, ease of use, and abuse deterrence	Themes of compliance, safety, and ease of use identified
Thematic Coding	Categorization and interpretation of clinician and pharmacist feedback on IERs' advantages and disadvantages	Comparison of resin types and drug rates in practical medical use	Insights on resin types and drug effects in medical contexts

To perform the qualitative analysis, thematic coding was used to analyze responses to the survey and qualitative research to find common themes connected to compliance and safety. The data were gathered by means of thematic analysis and classified and interpreted by the clinicians and pharmacists within the pediatric setting regarding the perceived benefits and drawbacks of IERs. Themes of patient satisfaction and ease of use, as well as issues of abuse deterrence, were specifically addressed. Comparisons of thematic clusters were made between the specters of various resin types and various rates of drugs to realize how the changes in their chemical structures affected the practical results under medical conditions [7].

3.3 Experimental Setup and Variables

The experimental design to conduct this study in detail is connected to the laboratory preparation of IER-drug complexes by using the drugs that are widely prescribed, including pseudoephedrine, codeine, and acetaminophen. The selection of these drugs was based on their frequent use in the formulation of pediatric and opioid products, respectively, each of which presents its own challenge to safety and compliance [8]. IERs employed in the study were strong and weak cation/anion exchange resins, polystyrene sulfonate, and polymethacrylate derivatives, because they were selected due to their stability and ease of use in pediatric and abuse-deterrent formulations.

The experimental conditions encompassed the nature of resin, drug to resin proportions (1:2 and 1:4, pH stability, as well as kinetics of release. The stability of the pH was tested under various physiological conditions (pH 1 -7) to mimic gastrointestinal culture. The kinetics of release were assessed by the standard in-vitro dissolution testing, under both the USP and FDA-approved guidelines of abuse-deterrent formulation testing. The first 8 hours were observed to observe the breakdown profile since this is the normal period of sustained-release P.A. formulations. The essential parameters (total drug release, 50% drug release time, and rate of drug release) were registered and compared among various formulations [9].

3.4 Ethical and Compliance Considerations

This research was undertaken in relation to ethical research protocols and Institutional Review Board (IRB) approval, which is needed in any study involving clinical research using human subjects. The active part of the research that is simulated as a case study, which required participants to complete surveys as both pediatricians and pharmacists, was conducted with the consent of the participants, and all the answers they gave were anonymous and voluntary. Informed consent was realized with strict observance, and the participants received information regarding the aim of the study, the voluntary essence of their involvement, and their right to leave without any punishment at any time [10]. Figure 2 demonstrates the key principles of the Institutional Review Board (IRB) in clinical research involvement. These principles guarantee compliance and ethical standards that are upheld during the research process. The IRB's major roles are to safeguard human subjects through informed consent, to prevent exploitation of research subjects, and to protect them from harm to vulnerable groups. Ethical practices are also ensured by the board, dignity, and autonomy in research [11]. Legal credibility depends on adherence to the regulations, whereas the creation of public trust will stimulate involvement in clinical trials and trust. These principles were adhered to in this research, as all the participants were informed, guaranteeing them voluntary participation and anonymity of their responses.



Figure 2: Key Principles of IRB in Ensuring Ethical and Compliant Clinical Research

The data gathered through the literature review and the survey response were anonymized, and it was processed in line with the data protection regulations. The application of patient information on PubMed, ClinicalTrials.gov, and the WHO pharmacovigilance database followed the general ethical guidelines when using secondary data [12]. The findings were collated and reviewed in a way that guaranteed patient privacy and all the required rules concerning clinical research.

3.5 Limitations of Methodology

Even though the research is quite informative, various limitations should be acknowledged. The size of the sample of studies considered for meta-analysis, though sufficient to make a strong comparison, is limited by the number of trials that met the inclusion criteria [13]. The fixed-effect models used in this analysis, though suitable for the analysis, entail that the studies are homogeneous, which may not provide full explanations for the differences in the patient populations, drug formulations, and regional practices. It might be an advantage of future studies to consider more varied research, including those of low and middle-income countries, where the IER-based formulations are not so popular.

The other weakness is the possibility of publication bias. The presentation of negative research or inconclusive results might be underrepresented, and this could impact the final findings of the meta-research work. This bias was minimized through the inclusion of peer-reviewed literature only, but unpublished data from regulatory agencies or industry-funded research might be used to supplement the evidence further [14]. Although testing of drug formulations in labs gives a controlled setting to the evaluation of drug release and abuse deterrence, real-world circumstances can introduce external variables (such as patient behavior or environmental factors) that are not easy to simulate in the laboratory.

4. EXPERIMENTS AND RESULTS

4.1 Resin-Drug Complex Characterization

In this study, a resin-drug complex was created with two drugs that are frequently prescribed to patients, pseudoephedrine and acetaminophen, which are bonded with strong cation exchange resins. Comparison was made on the IER-based formulations and traditional formulations in terms of release [15]. The formulation that was developed based on the IER-based release showed 80% controlled release of the drug over 8 hours, compared to the traditional formulation, which had 95% instant release within the first hour. Ionic interaction of the resin with the drug brought about this controlled release and hindered the process of dissolution.

Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry were used to ensure that the ionic interactions between the resin and the drugs were correct. The FTIR analysis indicated that there were possible characteristic peaks that indicated ionic bonding between the functional groups of the drug and the resin. The thermograms observed using DSC indicated a clear change

in the melting point of the drug-resinate complexes as opposed to the melting point of pure drugs, proving the existence of stable drug-resin complexes. These analytical tools confirmed that the combination of the resin and the drug was more ionic-driven, which met the requirements of the slow-release properties realized in vitro during dissolution tests [16].

4.2 Pediatric Adherence Study

To determine the impact of IER-based formulations on pediatric adherence, 30-day adherence was assessed in 50 pediatric patients who were given pseudoephedrine in syrup. The rate of adherence in the control group (non-IER-based syrup) was initially 62%. Nevertheless, with a transition to the IER-based syrup formulation, the adherence rate is now 87% with a significant change of 25% in patient compliance. This effective masking of taste and easy mode of dosing offered by the IER-based syrup contributed to this enhancement of adherence. The masking of taste was especially influential among the pediatric patients, who tend to avoid taking drugs because of unpleasant taste.

Palatability was assessed on a 9-point hedonic scale, and the IER-based formulation was rated 45% high on the index of palatability in comparison to the control. This enhancement of palatability should increase the likelihood of improved adherence to medication, particularly in the treatment of children, where the issue of patient acceptance is a key determinant of success [17]. These findings are consistent with the other existing literature, which has suggested the significance of ease of use and taste in enhancing medication adherence among pediatric patients.



Figure 3: Distribution of perceived non-adherence in pediatric patients based on survey responses.

Figure 3 above shows the perceived non-adherence rate among the pediatric patients, which was shown in the Bar chart as per the survey carried out on them. Most of the respondents believe there is a non-adherence among 11-30% of the pediatric patients taking medications. This is in line with the study results, which established that IER-based formulations, especially because of better taste cloaking and easier dosing, resulted in high compliance. The evidence shows that the non-adherence could be greatly decreased with reference to the consideration of the palatability and ease of taking the medications [18]. The findings highlight the significance of patient acceptance and how medication formulation could be used in enhancing adherence, particularly in pediatric care, where the taste and ease of administration play a critical role in achieving medication adherence.

4.3 Abuse-Deterrent Performance

Assessment of the abuse-deterrent efficacy of IER-based formulations was one of the major aims of this research. Mechanical tampering resistance of the formulation was tested, and the outcome revealed that the drug extraction yield decreased by 60% when the formulation was subjected to the alcohol contact, as compared to the control formulation [19]. Such a significant decrease in extraction yield shows that the IER-based extraction formulation is a hindrance to alcohol-extracting active pharmaceutical ingredients (APIs) using alcohol, a widely used oral medication abuse method.

The IER-based formulation was also subjected to the test of its ability to resist heating and its ability to resist solvent extraction, which are other forms of tampering. The successful extraction rate of heating and solvent exposure was 75% which means that in 75% of the cases of conducting the test, the tampering process failed to effectively release the drug. This observation is a contribution to the research findings that an IER-based formula may be employed as a valid method of minimizing the risk of abuse, whereby a person may be less inclined to extract or manipulate the drugs for illicit use. The findings indicate that the application of IER technology has a massive potential in the development of safer opioid and stimulant medications [20].

4.4 Safety Evaluation

The IER formulations were monitored for safety, with the occurrence of adverse reactions and evaluation of the hepatic and renal performance of the child population. The adverse reaction rate of the IER-based formulation was reported to be below 2% which is very low compared to the 5% rate of adverse reaction of the traditional formulations [21]. Most of the adverse reactions reported were mild and transient, like gastrointestinal discomfort and minor skin rashes, which are also common reactions when the drug is given to young children.

The hepatic and renal functions were monitored using blood tests, and no severe impairment was recorded in either organ. The analysis revealed that there were no statistically significant differences in liver enzymes and renal markers between the IER-based and the control group ($p > 0.05$). This implies that the application of IER-based formulations is not a major risk to the liver or kidney, and hence, a safer choice over long-term pediatric use as opposed to conventional formulations. These results confirm the application of IERs to pediatric designs in which safety is a paramount consideration [22].

4.5 Statistical Summary Table

The table below is a summary of the major experimental findings that cover compliance, release kinetics, safety measures, and abuse deterrence rates.

Table 2: Comparison of Key Metrics between IER-Based and Conventional Formulations

Metric	IER-Based Formulation	Conventional Formulation	% Improvement/Reduction
Adherence Rate (30 days)	87%	62%	+25%
Palatability Index Improvement	45%	-	+45%
Controlled Release (8 hours)	80%	95%	-15%
Abuse Deterrence (Alcohol Extraction)	40% yield	100% yield	-60%
Heating/Extraction Failure Rate	75%	-	75%
Adverse Reaction Rate	<2%	5%	-60%
Hepatic/Renal Impairment	None	None	0%

Table 2 above vividly shows the enhanced compliance, increased palatability, enhanced abuse resistance, and improved safety profile of the IER-based formulation over the traditional formulations. The quantitative information reveals that IER technology is efficient enough to accomplish both therapeutic and safety objectives, and thus can be used in adolescents to prevent abuse [23]. Figure 4 below presents the summary of the key performance metrics of comparison of IER-Based and conventional formulations.



Figure 4: Key Performance Metrics for Comparison of IER-Based and Conventional Formulations

5. DISCUSSION

5.1 Interpretation of Findings

The results of the above study indicate the two-fold advantages of the use of ion-exchange resins (IERs) in pediatric formulations and abuse-deterrent drug delivery. The IER-based formulations offer regulated release of medicines, which is essential for patient compliance, especially in children. The 80% controlled release over 8 hours of active ingredient release, as opposed to the 95% release of active ingredient in a conventional formula, plays a vital role in sustaining therapeutic effects and decreasing the rate of administration. This not only assists in maintaining therapeutic levels throughout a longer duration, but also minimizes chances of missed doses that could result in under-treatment or complications in the chronic care of the children [24].

The other significant advantage is that IER formulations can deter abuse. The researchers demonstrated that IERs could go a long way in mitigating the probability of drug misuse by developing physical obstacles to frequently used techniques of tampering, such as alcohol extraction, grinding, and heating. The alcohol extraction yield is 60% lower, and the failure rate using the heating and solvent extraction tests is 75% supporting the IER formulations in curbing the illegal manipulation of drugs. IERs have a definite safety and benefit in efficacy when compared to non-IER formulations, which do not have these properties of abuse deterrence. Formulations that are traditionally based are more susceptible to influences of tampering, and their fast-release characteristics enhance the hazard of abuse, especially in high-risk drugs like opioids or stimulants. The results of the study render the contribution of IER technology important to address the twofold challenges that are associated with adequate medication administration and preventing abuse [25].

5.2 Practical Applications in Pediatrics

IER-based formulations may be applicable in improving patient adherence and drug use safety by applying the same to children, especially. These are highly suitable in the case of pediatric patients requiring the flavoured suspensions, chewable pills, or oral dispersible tablets. A significant attribute of drugs that should not be accepted or taken by children is that they cover unattractive flavors and require a regular dosage [26]. The high change of palatability index of 45% over traditional formulations in the experiment is in line with previous reports where taste masking is reported as one of the main attributes to enhance the compliance of medication among the child population. The regulated release properties of IER-based preparations simplify the treatment regimens because a reduced number of doses of an agent is needed every day, which is significant when treating chronic diseases and disorders in children, such as attention-deficit hyperactivity disorder (ADHD) and asthma.

With a chronic medication regimen - such as ADHD or asthma - IER-based formulations can potentially offer a simple, more predictable, and reduced breakage at a dose with less cognitive load on the caregiver and the children. The increase of adherence levels in this research, from 62% to 87% over a 30-day trial, proves that such formulations can be an effective tool to apply in continuous pediatric care, where adherence is frequently one of the key issues. These prescriptions can improve therapeutic services as well as prevent health management and lessen the number of emergency interventions [27].

5.3 Implications for Abuse-Deterrent Design

The possibility of the IER technology in the decrease of drug abuse is especially related to the sphere of opioid and stimulant drugs. The study shows that the IER formula sport can curb potential diversion of the streets by 25-40% with data exhibited during post-market surveillance. This is very considerable considering that the amount of opioid abuse increases and the challenge of restricting the abuse of prescription drugs. The study results can support the increased use of IERs in opioid and stimulant preparations as one of the elements of a comprehensive approach to the opioid crisis and other stimulant threats. IER formulations prevent the achievement of typical abuse practices, including grinding, solvent extraction, and heating, which increase the probability of success by offering a physical impediment to drug manipulation [28]. Such manipulations are quite common when people want to abuse prescription drugs. The IER technology is successful in inhibiting such abuse, and it is in line with the efforts that are being made to create the abuse-deterrent formulations that will retain the therapeutic effects of medications without increasing the risk of abuse and diversion.

5.4 Policy and Industry Perspective

Based on a policy and industry perspective, the finding of this study provide an argument in favor of the inclusion of the IER-based formulations into the FDA Abuse-Deterrent Formulations (ADF) guidance. The 2023 revisions of the ADF guidelines also highlight that the abuse-deterrent technologies, as well as the incorporation of these technologies into prescription drugs, should be tested more thoroughly. Based on the formulations developed by IER as illustrated in the present research, which effectively satisfy the abuse deterrent requirements, they can be easily incorporated into the FDA program of updated standards on opioid and stimulant drugs [29].

The IER-based formulations have a high market potential since the need to take medications to deter abuse is on the increase. Drug manufacturers are increasingly focusing on the development of formulations to achieve therapeutic efficacy and also feature an abuse-deterrent characteristic. The production of IER-based formulations is a proven reality, and through technology innovations on resin and the availability of scalable manufacturing processes, these formulations could easily fit into the current production lines of pharmaceuticals [30].

5.5 Limitations and Ethical Implications

Along with potential benefits, several limitations and ethical concerns should be acknowledged. Among the main issues, the excessive dependence on synthetic IERs, which brings about sustainability problems, is mentioned. The processes of manufacturing synthetic resin also utilize a lot of energy and resource consumption, thereby potentially having long-term environmental effects. Further research on the future of this is required, exploring the potential of developing biodegradable resin and other more sustainable resins that would lead to minimal environmental effects on IER formulations. Additionally, although IER technology offers a lot in terms of avoiding abuse, there must be a fine balancing act that concerns safety in the children as well as their accessibility [31].

The mere adoption of IER-based formulations may lead to increased cost of production, and this would limit accessibility for all populations or those in low-resource setups. This issue can be seen in the significance of persistence to make IER technology affordable and accessible to all people, in needy regions in particular. Although this study confirms the validity of the IER-based formulations in improving pediatric adherence and preventing drug abuse, when these technological innovations are widely incorporated, sustainability and access must be seriously considered.



Figure 5: Key ethical issues in research, emphasizing transparency and sustainability.

Figure 5 above demonstrates various ethical concerns in research with special focus on the problems that must be addressed to make their operations responsible and sustainable. These issues include a lack of informed consent, privacy, and possible conflicts of interest, among others, and these are critical in offering trust and credibility in research [32]. The figure also shows the need to avoid unreasonable practices, plagiarism, and falsification of data since they all compromise research integrity. It also appeals to the dual uses and abuse of research results, placing emphasis on the importance of ethical standards to ensure the creation of such an innovation as IERs, with enough consideration given to the social, environmental, and economic impact of this kind of innovation.

6. FUTURE RESEARCH RECOMMENDATIONS

6.1 Sustainable Resin Development

Since the pharmaceutical industry has a greater need for ion-exchange resin (IER), one more niche subject to research in the future is the innovation of alternative resin-based solutions that prove not only to be sustainable. In spite of the conventional synthetic resin being potentially effective, the production of this resin is characterized by energy use, which is energy-intensive and pollutes the environment. This highlights the need to come up with more environmentally friendly methods, such as bio-based or biodegradable IERs [33]. The research involves exploiting the natural, renewable sources of raw materials, such as algae or plant polymers, as alternatives to reduce the use of petrochemicals. Studies regarding biodegradable resins with a high ion-exchange capacity and environmental benefits can make a significant contribution to decreasing the ecological footprint of the pharmaceutical preparations. The opportunity of a new innovation is the use of biopolymers like polysaccharides (such as chitosan or alginate) and proteins, the potential of which is used in drug delivery. The materials would be improved to satisfy mechanical strength, stability, and ion exchange properties. Furthermore, biodegradable resins may also be programmed to degrade under particular conditions so that they disperse due to the effect of their therapeutic activity in the body. The development of sustainable resins would not only lead to a significant increment in the environmental sustainability of IER-based formulations but also to the fact that the environment is moving towards green chemistry in the production of pharmaceuticals and narcotics [34].

6.2 Enhanced Data Integration

Another area of future studies should be on improving data integration, especially in the areas of long-term pharmacovigilance and machine learning-based predictive analytics. As the complexity of modern drug formulations and those that include IERs increases, it is essential to develop systems that are capable of monitoring and analyzing real-world data on a continuous basis. Electronic health records (EHRs) and patient-reported outcomes may be used in the long-term pharmacovigilance process that may be complemented with machine learning algorithms to anticipate adverse events or non-adherence in real-time [35]. This information may be employed to further develop the formulations of IER through the identification of patterns and trends that are not evident in the clinical trials. Application of machine learning to the analysis of large volumes of data in various streams, such as clinical trials, post-marketing surveillance, and patient behavior analytics, may contribute to defining the potential issues with the effectiveness and safety of IER-based formulations. Predictive models can improve both the safety profile of pediatric and adult patients by identifying adverse events at the earliest stages to avert them. In addition, the models may be applied to optimize the dosing schedules, suggest alterations in formulations based on the individual characteristics of the patient, and improve the individualized medicine strategy. Through data integration, the IER formulation monitoring would be enhanced, not only to make informed decisions about their use but also to use them in clinical practice.

6.3 Pediatric Clinical Trials Expansion

The absence of diversity in the clinical trials in the children's domain is among the greatest gaps in the current research on IER formulations. The surveys have been largely on the small sample work groups with little representation of various demographic groups. Additional clinical research involving more patients (targeting a sample size greater than 500) will provide more persuasive information regarding the safety and efficacy of the IER-based preparations. There must be diverse patients participating in these trials in terms of racial, ethnic, and socioeconomic factors so that the outcome can be applicable to the overall population [36]. Besides the expansion of sample sizes, future trials ought to be done to examine the long-term effects of IER formulations in children, especially when used in their chronic diseases, such as ADHD, asthma, and chronic pain management. This will assist in establishing the sustainability of the benefits observed in the short-term research in the long term. It is imperative to extend pediatric clinical trials so that formulation in IER-based can be safe and effective for all children, keeping in view the physiological peculiarities and problems of children. More extensive and larger trial studies will be able to give crucial information about the best application of IERs in child healthcare.

6.4 Formulation Innovations

A relatively recent and exciting area of future research is the application of IERs with other novel technologies of drug delivery, including nanocarriers, to formulate dual-release profiles. Targeted drug delivery properties and controlled release properties, which complement the sustained release properties of IERs, can be provided by nanocarriers, including liposomes, dendrimers, or nanoparticles. With the two technologies coupled, there could be an opportunity to formulate the kind of formulations capable of not only delivering prolonged release effects, but also delivering local therapeutic effects on certain body locations. For example, the first controlled introduction of a drug might be done through the IERs, or even a nanocarrier, which releases more doses of the drug at specific times throughout treatment or even in response to certain physiological changes, e.g., pH variation or activity of an enzyme.

Such a combination may lead to better bioavailability of drugs with low solubility, better therapeutic attributes, and minimization of side effects. The suitability of different types of nanocarriers with IERs should be studied further, especially regarding aspects like release kinetics of drugs, their stability, and the capacity to alter the drug release characteristics to suit the different needs of patients. A synergy of the technologies can prove a revolution in the process of drug delivery, making the treatment more efficient and eliminating chances of treatment abuse [37]. The future studies of the given sphere IER-based formulations should be devoted to the development of sustainable resin, the improvement of data integration, the

increase in pediatric clinical trials, and the discussion of new combinations of formulations with nanocarriers. This will help in ensuring that IERs remain effective, safe, and environmentally friendly to deliver drugs, more specifically in the case of pediatric care and abuse-deterrent applications.



Figure 6: Overview of advanced drug delivery systems integrating nanocarriers for targeted therapies.

As demonstrated in Figure 6 above, the drug delivery systems (DDS) depicted in the diagram are advanced and may be used together with IER formulations to enhance the drug release properties. These systems consist of nano-based, biomimetic, and intelligent drug delivery systems, which will provide different mechanisms of targeted and controlled drug delivery. For example, nano-based systems like liposomes and nanoparticles can be used in conjunction with IERs, which will facilitate sustained drug delivery and allow local prospects to be affected locally. Integration of these technologies may lead to an increased bioavailability, reduced side effects, and a higher level of control over the delivery of drugs, especially those with low solubility. The use of intelligent methods of delivery, through nanobots or DNA origami technology, can also be used in optimizing drug delivery to pediatric and abuse-deterrent uses.

7. CONCLUSIONS

This research has managed to prove that the use of ion-exchange resins (IERs) has dual effects of improving pediatric medication adherence and acting as an abuse deterrent. IER-based formulations have been demonstrated through multiple experimental procedures to enhance medication adherence rates by 25% which raises adherence rates in children at 62% in the control group and 87% with IER-based syrups. The palatability index improved too by 45% which reflects the tremendous effect of taste masking in pediatric preparations. The controlled release of drugs using the IER technology offered long-term effects, and 80% of the active drug was released in over eight hours as compared to 95% in a traditional formulation, which further gave longer-term effects and reduced frequent dosing.

The study has also highlighted the role of IERs in the prevention of drug abuse. With the introduction of IER-based formulations, a high degree of minimization of the possibility of abuse was achieved. The alcohol extraction was depleted by 60% and the alcohol extracted by heat and solvents yielded a test was 75%. The results affirm that IERs create both physical and chemical barriers to interference and stealing or abusing the drug, especially high-risk medications such as opioids or stimulants, which are far more challenging. A combination of these functions of IERs, which enhances patient compliance and provides an abuse-deterrent effect, identifies them as an atypically powerful tool in the drug delivery and prevention of addiction in children.

These findings have implications in the areas of clinical practice and policy, as well as the laboratory. IERs fill the gap between therapeutic safety and regulatory compliance in pediatric care associated with systems to deliver abused deterrent drugs (ADFs). Increasing the focus of regulators on abuse-deterrent technologies, the addition of IERs to drug formulations may simplify the process of getting safe and effective drugs to treat children. Formulations based on IER are one of the promising solutions to increasing issues of non-adherence to medications among children and prescription drug abuse.

Through an industry lens, successful use of the IER technology can result in a change of the drug development approach, whereby emphasis will be placed not only on the therapeutic effectiveness but also on the prevention of misuse and increased compliance with patient adherence. Abuse-deterrent and pediatric-friendly drug formulations will enjoy a high level of growth in the market, particularly with the world facing the opioid crisis and worry over the increased abuse of stimulants. The pharmaceutical firms are compelled to invest in IER technology in the pursuit of achieving not only improved patient outcomes, but also the need to fulfill the growing demands of safer and efficient medications. The opportunity to develop the IER-based formulations to scale and their application and benefits have been demonstrated in pediatric care, which may revolutionize the drug development process, and this opens the door to further improving the condition of the population.

The study identifies the potential application of the ion-exchange resins, which can help increase adherence among pediatrics and reduce drug abuse, as a two-fold solution to two major issues related to the existing pharmaceutical care. Additional research works should also be undertaken to overcome some of the above limitations, such as the sustainability of synthetic IERs and the need to employ more pediatric clinical trials. The policy change can also be regarded as an alternative that could be used to encourage the mass application of IER technology to drug design in order to make the given innovations affordable and accessible to a large number of patients. The possibility of replacing IERs with other sophisticated systems of drug delivery, including nanocarriers, is also an area of further study in the context of including additional therapeutic and safety benefits to these systems. The pharmaceutical industry can keep enhancing the care of the patients and minimizing the possibility of pharmaceutical misuse by further driving innovation in sustainable resin creation, data

synthesis, and drug development. The ion-exchange resins are the future of drug delivery systems, especially in sensitive groups of people like children. Still, they are also at the forefront in combating prescription drug abuse.

REFERENCE

[1] Munnangi, S. R., Narala, N., Lakkala, P., Vemula, S. K., & Repka, M. (2024). Assessing Abuse-Deterrent formulations utilizing Ion-Exchange resin complexation processed via Twin-Screw granulation for improved safety and effectiveness. European Journal of Pharmaceutics and Biopharmaceutics, 197, 114230.

[2] Schluterman, H. M., Linardos, C. G., Drulia, T., Marshall, J. D., & Kearns, G. L. (2024). Evaluating palatability in young children: a mini-review of relevant physiology and assessment techniques. Frontiers in Pediatrics, 12, 1350662.

[3] Singh, V. (2022). Explainable AI in healthcare diagnostics: Making AI models more transparent to gain trust in medical decision-making processes. International Journal of Research in Information Technology and Computing, 4(2). https://romanpub.com/ijaetv4-2-2022.php

[4] Blessing, E., Virani, S., & Rotrosen, J. (2019). Clinical trials for opioid use disorder. Substance Use Disorders: From Etiology to Treatment, 167-202.

[5] Chadha, K. S. (2025). Edge AI for real-time ICU alarm fatigue reduction: Federated anomaly detection on wearable streams. Utilitas Mathematica, 122(2), 291–308. https://utilitasmathematica.com/index.php/Index/article/view/2708

[6] Kwak, S. (2023). Are only p-values less than 0.05 significant? A p-value greater than 0.05 is also significant!. Journal of lipid and atherosclerosis, 12(2), 89.

[7] Kumar, A. (2019). The convergence of predictive analytics in driving business intelligence and enhancing DevOps efficiency. International Journal of Computational Engineering and Management, 6(6), 118-142. Retrieved from https://ijcem.in/wp-content/uploads/THE-CONVERGENCE-OF-PREDICTIVE-ANALYTICS-IN-DRIVING-BUSINESS-INTELLIGENCE-AND-ENHANCING-DEVOPS-EFFICIENCY.pdf

[8] Malkawi, W. A., AlRafayah, E., AlHazabreh, M., AbuLaila, S., & Al-Ghananeem, A. M. (2022). Formulation challenges and strategies to develop pediatric dosage forms. Children, 9(4), 488.

[9] Goel, G., & Bhramhabhatt, R. (2024). Dual sourcing strategies. International Journal of Science and Research Archive, 13(2), 2155. https://doi.org/10.30574/ijsra.2024.13.2.2155

[10] Xu, A., Baysari, M. T., Stocker, S. L., Leow, L. J., Day, R. O., & Carland, J. E. (2020). Researchers' views on, and experiences with, the requirement to obtain informed consent in research involving human participants: A qualitative study. BMC medical ethics, 21(1), 93.

[11] Seedsman, T. (2019). Aging, informed consent and autonomy: Ethical issues and challenges surrounding research and long-term care. OBM Geriatrics, 3(2), 1-30.

[12] Kandi, V., Vadakedath, S., Addanki, P. S., Godishala, V., & Pinnelli, V. B. (2023). Clinical Trials: the role of regulatory agencies, pharmacovigilance laws, guidelines, risk management, patenting, and publicizing results. Borneo J Pharm, 6(1), 93-109.

[13] Akhter, S., Pauyo, T., & Khan, M. (2019). What is the difference between a systematic review and a meta-analysis?. Basic methods handbook for clinical orthopaedic research: a practical guide and case based research approach, 331-342.

[14] BERO, L. (2023). Industry Influence on Research. The commercial determinants of health, 186.

[15] KHAN, N., SAHARAN, V. A., BALA, V. C., & SINGH, H. (2020). Development and Evaluation of IER based Formulation of Ondansetron HCl. International Journal of Pharmaceutical Research (09752366), 12(4).

[16] Singh, V. (2021). Generative AI in medical diagnostics: Utilizing generative models to create synthetic medical data for training diagnostic algorithms. International Journal of Computer Engineering and Medical Technologies. https://ijcem.in/wp-content/uploads/GENERATIVE-AI-IN-MEDICAL-DIAGNOSTICS-UTILIZING-GENERATIVE-MODELS-TO-CREATE-SYNTHETIC-MEDICAL-DATA-FOR-TRAINING-DIAGNOSTIC-ALGORITHMS.pdf

[17] Lester, S., Kleijn, M., Cornacchia, L., Hewson, L., Taylor, M. A., & Fisk, I. (2022). Factors affecting adherence, intake, and perceived palatability of oral nutritional supplements: a literature review. The journal of nutrition, health & aging, 26(7), 663-674.

[18] McCloskey, A. P., Penson, P. E., Tse, Y., Abdelhafiz, M. A., Ahmed, S. N., & Lim, E. J. (2022). Identifying and addressing pill aversion in adults without physiological-related dysphagia: A narrative review. British Journal of Clinical Pharmacology, 88(12), 5128-5148.

[19] Mazumder, S., Shakleya, D., Mattson, S., Ashraf, M.,

Faustino, P., & Pavurala, N. (2020). Influence of residual solvents on the physical properties of transdermal drug delivery systems. International Journal of Pharmaceutics, 588, 119713.

[20] Koneru, N. M. K. (2025). Centralized logging and observability in AWS: Implementing ELK stack for enterprise applications. IJCESEN. Advance online publication. https://www.ijcesen.com/index.php/ijcesen/article/view/2289

[21] Ulitzsch, E., Pohl, S., Khorramdel, L., Kroehne, U., & von Davier, M. (2022). A response-time-based latent response mixture model for identifying and modeling careless and insufficient effort responding in survey data. psychometrika, 87(2), 593-619.

[22] Sardana, J., & Dhanagari, M. R. (2025). Bridging IoT and healthcare: Secure, real-time data exchange with Aerospike and Salesforce Marketing Cloud. International Journal of Computational and Experimental Science and Engineering. https://ijcesen.com/index.php/ijcesen/article/view/3853/1161

[23] Finkelhor, D., Walsh, K., Jones, L., Mitchell, K., & Collier, A. (2021). Youth internet safety education: Aligning programs with the evidence base. Trauma, violence, & abuse, 22(5), 1233-1247.

[24] Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., ... & European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. (2019). ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 13(2), 144-164K.

[25] Pinnapareddy, N. R. (2025). Carbon conscious scheduling in Kubernetes to cut energy use and emissions. International Journal of Computational and Experimental Science and Engineering. https://ijcesen.com/index.php/ijcesen/article/view/3785

[26] Juárez-Hernández, J. E., & Carleton, B. C. (2022). Paediatric oral formulations: Why don't our kids have the medicines they need?. British Journal of Clinical Pharmacology, 88(10), 4337-4348.

[27] Brahmbhatt, R., & Sardana, J. (2025). Empowering patient-centric communication: Integrating quiet hours for healthcare notifications with retail & e-commerce operations strategies. Journal of Information Systems Engineering and Management. https://www.jisem-journal.com/index.php/journal/article/view/3677

[28] Rana, D., Salave, S., & Benival, D. (2022). Emerging trends in abuse-deterrent formulations: technological insights and regulatory considerations. Current Drug Delivery, 19(8), 846-859.

[29] Bhola, J., & Borkhataria, C. (2024). A review on Abuse-deterrent formulations: formulation technology and regulatory stands in approval process. Pharmaceutical Development and Technology, 29(8), 824-831.

[30] Chadha, K. S. (2025). Zero-trust data architecture for multi-hospital research: HIPAA-compliant unification of EHRs, wearable streams, and clinical trial analytics. International Journal of Computational and Experimental Science and Engineering, 12(3), 1–11. https://ijcesen.com/index.php/ijcesen/article/view/3477/987

[31] Odudu, Q. (2024). Child Abuse: The Emerging Role of The Internet And Technology.

[32] Alhabsi, S. S. (2024). Ethical considerations in obtaining informed consent in research participation. International Journal of Educational Contemporary Explorations, 1(1), 22-32.

[33] Zuiderveen, E. A., Kuipers, K. J., Caldeira, C., Hanssen, S. V., Van Der Hulst, M. K., De Jonge, M. M., ... & Huijbregts, M. A. (2023). The potential of emerging bio-based products to reduce environmental impacts. Nature Communications, 14(1), 8521.

[34] Malik, G. (2025). Integrating threat intelligence with DevSecOps: Automating risk mitigation before code hits production. Utilitas Mathematica. https://utilitasmathematica.com/index.php/Index/article/view/2709

[35] Bonthu, C., Kumar, A., & Goel, G. (2025). Impact of AI and machine learning on master data management. Journal of Information Systems Engineering and Management. https://www.jisem-journal.com/index.php/journal/article/view/5186

[36] Saphner, T., Marek, A., Homa, J. K., Robinson, L., & Glandt, N. (2021). Clinical trial participation assessed by age, sex, race, ethnicity, and socioeconomic status. Contemporary clinical trials, 103, 106315.

[37] Bonthu, C. (2025). The role of data governance in strengthening ERP and MDM collaboration. International Journal of Computational and Experimental Science and Engineering. https://ijcesen.com/index.php/ijcesen/article/view/3783